The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2016 | Targeted therapy of AML
Mark Levis, MD, PhD from The Johns Hopkins University, Baltimore, MD discusses treatment of acute myeloid leukemia (AML) patients. Although there is still little understanding of the pathogenesis of AML, practitioners do know to target CD19 – a B-cell specific surface protein. Two targeted therapies are currently available in AML therapy, inotuzumab and blinatumomab. Inotuzumab ozogamicin is very indiscriminate while contrastingly blinatumomab, a bispecific T-cell engager (BiTEs), is very specific. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
